Literature DB >> 18387851

Towards gene therapy for Parkinson's disease.

Stéphane Palfi.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18387851     DOI： 10.1016/S1474-4422(08)70066-8

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  7 in total

Review 1.  Missing pieces in the Parkinson's disease puzzle.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

Review 2.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

Review 3.  alpha-Synuclein: a therapeutic target for Parkinson's disease?

Authors:  Kathleen A Maguire-Zeiss
Journal:  Pharmacol Res       Date:  2008-09-16       Impact factor: 7.658

4.  Perfused human organs versus Mary Shelley's Frankenstein.

Authors:  Lawrence Leung
Journal:  J Transl Med       Date:  2009-01-23       Impact factor: 5.531

5.  Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.

Authors:  Jamie L Eberling; Adrian P Kells; Philip Pivirotto; Janine Beyer; John Bringas; Howard J Federoff; John Forsayeth; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

Review 6.  Consideration of gene therapy for paediatric neurotransmitter diseases.

Authors:  Michael Rotstein; Un Jung Kang
Journal:  J Inherit Metab Dis       Date:  2009-03-03       Impact factor: 4.982

7.  Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors.

Authors:  Nicolas Merienne; Juliette Le Douce; Emilie Faivre; Nicole Déglon; Gilles Bonvento
Journal:  Front Cell Neurosci       Date:  2013-07-05       Impact factor: 5.505
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.